REFERENCES
2. Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer - an overview and update. Mol Cell Endocrinol 2015;418:220-34.
3. Pan H, Gray R, Braybrooke J, et al. EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017;377:1836-46.
4. Kostev K, Kalder M. 20-year risk of breast cancer recurrence. Breast Cancer Res Treat 2018;168:765-6.
5. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions from a new method of treatment, with illustrative cases. Trans Med Chir Soc Edinb 1896;15:153-179.
6. Lonning PE. Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. Ther Adv Med Oncol 2012;4:127-37.
7. Barrios CH, Sampaio C, Vinholes, Caponero R. What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann Oncol 2009;20:1157-62.
8. Cole MP, Jones CTA, Todd IDH. A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br J Cancer 1971;25:270-5.
9. Reinert T, Barrios CH. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review. Ther Adv Med Oncol 2017;9:693-709.
10. Robertson JFR, Di Leo A, Johnston S, et al. Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies. NPJ Breast Cancer 2021;7:11.
11. Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 2016;388:2997-3005.
12. Robertson JFR, Cheung KL, Noguchi S, et al. Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. Eur J Cancer 2018;94:206-15.
13. Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol 2015;33:3781-7.
14. Robertson JFR, Paridaens RJ, Lichfield J, Bradbury I, Campbell C. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. Eur J Cancer 2021;145:19-28.
15. Josefsson ML, Leinster SJ. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy. Breast 2010;19:76-83.
16. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425-39.
17. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35.
18. Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 2019;29:116-24.
19. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381:307-16.
20. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 2019;382:514-24.
21. Huang M, Zhang J, Yan C, Li X, Zhang J, Ling R. Small molecule HDAC inhibitors: Promising agents for breast cancer treatment. Bioorg Chem 2019;91:103184.
22. Clarke R, Tyson JJ, Tan M, et al. Systems biology: perspectives on multiscale modeling in research on endocrine-related cancers. Endoc Relat Cancer 2019;26:R345-68.
23. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39.
24. Fang L, Liu YJ, Zhang YW, et al. Comparison of proteomics profiles between xenografts derived from cell lines and primary tumors of thyroid carcinoma. J Cancer 2021;12:1978-89.
25. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res 2011;13:215.
26. Hatzis C, Bedard PL, Juul BN, et al. Enhancing reproducibility in cancer drug screening: how do we move forward? Cancer Res 2014;74:4016-23.
27. Lippman ME, Bolan G. Oestrogen-responsive human breast cancer in long term tissue culture. Nature 1975;256:592-3.
28. Jordan VC. Prolonged antioestrogenic activity of ICI 46,474 in the ovariectomized mouse. J Reprod Fertil 1975;42:251-8.
29. Jordan VC. 50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened? Endocr-Relat Cancer 2021;28:R11-30.
30. Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol 2015;12:381-94.
31. Fan M, Xia P, Clarke R, Wang Y, Li L. Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer. Nat Commun 2020;11:4861.
32. Percie du Sert N, Ahluwalia A, Alam S, et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol 2020;18:e3000411.
33. Svendsen P, El-Galaly TC, Dybkaer K, et al. The application of human phase 0 microdosing trials: A systematic review and perspectives. Leuk Lymphoma 2016;57:1281-90.
34. Arnedos M, Roulleaux Dugage R, Perez-Garcia J, Cortes J. Window of Opportunity trials for biomarker discovery in breast cancer. Curr Opin Oncol 2019;31:486-492.
35. Wilson JL, Cheung KWK, Lin L, et al. Scientific considerations for global drug development. Sci Transl Med 2020;12:eaax2550.
36. Zhu Y, Wang A, Liu MC, et al. Estrogen receptor alpha (ER) positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures. Int J Oncol 2006;29:1581-9.
37. Cope LM, Fackler MJ, Lopez-Bujanda Z, et al. Do breast cancer cell lines provide a relevant model of the patient tumor methylome? PLoS ONE 2014;9:e105545.
38. Clarke R, Brünner N, Thompson EW, et al. The inter-relationships between ovarian-independent growth, antiestrogen resistance and invasiveness in the malignant progression of human breast cancer. J Endocrinol 1989;122:331-40.
39. Creighton CJ, Cordero KE, Larios JM, et al. Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol 2006;7:R28.
40. Kao J, Salari K, Bocanegra M, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 2009;4:e6146.
41. Wen Y, Wei Y, Zhang S, et al. Cell subpopulation deconvolution reveals breast cancer heterogeneity based on DNA methylation signature. Brief Bioinform 2017;18:426-40.
42. Nass N, Kalinski T. Tamoxifen resistance: from cell culture experiments towards novel biomarkers. Pathol Res Pract 2015;211:189-97.
43. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
44. Vincent KM, Findlay SD, Postovit LM. Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles. Breast Cancer Res 2015;17:114.
45. Jiang G, Zhang S, Yazdanparast A, et al. Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics 2016;17 Suppl 7:525.
46. Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res 2016;14:3-13.
47. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013;4:2126.
48. Kenny PA, Lee GY, Myers CA, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007;1:84-96.
49. Wong C, Chen S. The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance. J Steroid Biochem Mol Biol 2012;131:83-92.
50. Chen S, Masri S, Hong Y, et al. New experimental models for aromatase inhibitor resistance. J Steroid Biochem Mol Biol 2007;106:8-15.
51. Yue W, Zhou D, Chen S, Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 1994;54:5092-5.
54. Clarke R, Kraikivski P, Jones BC, Sevigny CM, Sengupta S, Wang Y. A systems biology approach to discovering pathway signaling dysregulation in metastasis. Cancer Metastasis Rev 2020;39:903-18.
55. Stuelten CH, Parent CA, Montell DJ. Cell motility in cancer invasion and metastasis: insights from simple model organisms. Nat Rev Cancer 2018;18:296-312.
56. Aitman TJ, Boone C, Churchill GA, Hengartner MO, Mackay TF, Stemple DL. The future of model organisms in human disease research. Nat Rev Genet 2011;12:575-82.
57. Olarerin-George AO, Hogenesch JB. Assessing the prevalence of mycoplasma contamination in cell culture via a survey of NCBI's RNA-seq archive. Nucleic Acids Res 2015;43:2535-42.
58. Iyama K, Zhang S, Lo SC. Effects of mycoplasmal LAMPs on receptor responses to steroid hormones in mammalian cells. Curr Microbiol 2001;43:163-9.
59. Laborda-Illanes A, Sanchez-Alcoholado L, Dominguez-Recio ME, et al. Breast and gut microbiota action mechanisms in breast cancer pathogenesis and treatment. Cancers (Basel) 2020;12:4016-23.
60. Chen J, Douglass J, Prasath V, et al. The microbiome and breast cancer: a review. Breast Cancer Res Treat 2019;178:493-6.
61. Somaschini A, Amboldi N, Nuzzo A, et al. Cell line identity finding by fingerprinting, an optimized resource for short tandem repeat profile authentication. Genet Test Mol Biomarkers 2013;17:254-9.
62. Nims RW, Reid Y. Best practices for authenticating cell lines. In Vitro Cell Dev Biol Anim 2017;53:880-7.
63. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
64. Lorsch JR, Collins FS, Lippincott-Schwartz J. Cell Biology. Fixing problems with cell lines. Science 2014;346:1452-3.
65. Buschhaus JM, Humphries BA, Eckley SS, et al. Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow. Oncogene 2020;39:5649-62.
66. Franco-Barraza J, Beacham DA, Amatangelo MD, Cukierman E. Preparation of extracellular matrices produced by cultured and primary fibroblasts. Curr Protoc Cell Biol 2016;71:10.
67. Justus CR, Leffler N, Ruiz-Echevarria M, Yang LV. In vitro cell migration and invasion assays. J Vis Exp 2014:51046.
68. Hafner M, Niepel M, Chung M, Sorger PK. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods 2016;13:521-7.
69. Eastman A. Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays. Oncotarget 2017;8:8854-66.
70. Haverty PM, Lin E, Tan J, et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature 2016;533:333-7.
71. Kennedy DG, van den Berg HW, Clarke R, Murphy RF. The effect of the rate of cell proliferation on the synthesis of methotrexate poly-γ-glutamates in two human breast cancer cell lines. Biochem Pharmacol 1985;34:3087-90.
72. Kreso A, O'Brien CA, van GP, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013;339:543-8.
73. Kooistra T, Opdenberg JP, Toet K, Hendriks HF, van den Hoogen RM, Emeis JJ. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo. Thromb Haemost 1991;65:565-72.
74. Soule HD, Vasquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a human breast carcinoma. J Natl Cancer Inst 1973;51:1409-16.
75. Agthoven T, van Agthoven TL, Portengen H, Foekens JA, Dorssers LC. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 1992;52:5082-8.
76. Clarke R, Brünner N, Katzenellenbogen BS, et al. Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells. Proc Natl Acad Sci U S A 1989;86:3649-53.
77. Brünner N, Boulay V, Fojo A, Freter C, Lippman ME, Clarke R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 1993;53:283-90.
78. Brünner N, Boysen B, Jirus S, et al. MCF7/LCC9: An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182, 780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 1997;57:3486-93.
79. Butler WB. Varied responses to retinoic acid of tamoxifen-sensitive and tamoxifen-resistant sublines of the human breast cancer cell line MCF-7. Proc Am Assoc Cancer Res 1989:30305.
80. Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,790 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 1994;54:1587-95.
81. Jensen BL, Skouv J, Lykkesfeldt AE. Differential regulation of specific genes in MCF-7 and the ICI 182,780-resistant cell line MCF-7182R-6. Br J Cancer 1999;79:386-92.
82. Naundorf H, Becker M, Lykkesfeldt AE, et al. Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. Br J Cancer 2000;82:1844-50.
83. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25.
84. Lewis JS, Osipo C, Meeke K, Jordan VC. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 2005;94:131-41.
85. Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005;97:1746-59.
86. Keydar I, Chen L, Karby S, et al. Establishment and characterization of a cell line of human carcinoma origin. Eur J Cancer 1979;15:659-70.
87. Murphy CS, Pink JJ, Jordan VC. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res 1990;50:7285-92.
88. Pink JJ, Bilimoria MM, Assikis J, Jordan VC. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer 1996;74:1227-36.
89. Park WC, Liu H, Macgregor SJ, Jordan VC. Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells. Int J Oncol 2005;27:1459-66.
90. Graham ML, Krett NL, Miller LA, et al. T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res 1990;50:6208-17.
91. Ribas R, Pancholi S, Guest SK, et al. AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo. Mol Cancer Ther 2015;14:2035-48.
92. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 1978;38:3352-64.
93. den Berg HW, Lynch M, Martin J, Nelson J, Dickson GR, Crockard AD. Characterization of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and stability of the resistant phenotype. Br J Cancer 1989;59:522-6.
94. den Berg HW, Martin J, Lynch M. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions. Br J Cancer 1990;61:504-7.
95. Long B, McKibben BM, Lynch M, van den Berg HW. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br J Cancer 1992;65:865-9.
96. Kangaspeska S, Hultsch S, Jaiswal A, et al. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. BMC Cancer ;2016:16:378.
97. Clarke R. Animal models of breast cancer: their diversity and role in biomedical research. Breast Cancer Res Treat 1996;39:1-6.
98. Clarke R. Animal models of breast cancer:experimental design and their use in nutrition and psychosocial research. Breast. Cancer Res Treat 1997;46:117-33.
99. Clarke R. Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 1996;39:69-86.
100. Clarke R. Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. Breast Cancer Res Treat 1997;46:255-78.
101. Shultz LD, Goodwin N, Ishikawa F, Hosur V, Lyons BL, Greiner DL. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc 2014;2014:694-708.
102. Percie du SN, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Exp Physiol 2020;105:1459-66.
103. Yamamoto S, Tanaka H, Kanamori T, Nobuhara M, Namba M. In vitro studies on potentiation of cytotoxic effects of anticancer drugs by interferon on a human neoplastic cell line (HeLa). Cancer Lett 1983;20:131-8.
104. Mantell N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
105. Hanfelt J. Statistical approaches to experimental design and data analysis of in vivo studies. Breast Cancer Res Treat 1997;46:279-302.
106. Rygaard K, Spang-Thomsen M. . "GROWTH"- a computer program for determination of mean growth curves and calculation of response to therapy of solid tumor xenografts. In: Wu B, Zheng J, editors. Immune-deficient animals in experimental medicine. Basel: Karger; 1989. p. 301-6.
108. Bulun SE, Lin Z, Imir G, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359-83.
109. Zhao H, Innes J, Brooks DC, et al. A novel promoter controls Cyp19a1 gene expression in mouse adipose tissue. Reprod Biol Endocrinol 2009;7:37.
110. Golovine K, Schwerin M, Vanselow J. Three different promoters control expression of the aromatase cytochrome p450 gene (cyp19) in mouse gonads and brain. Biol Reprod 2003;68:978-84.
111. Sflomos G, Dormoy V, Metsalu T, et al. A preclinical model for ERalpha-positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell 2016;29:407-22.
113. Murayama T, Gotoh N. Patient-derived xenograft models of breast cancer and their application. Cells 2019;8:621.
114. Holen I, Speirs V, Morrissey B, Blyth K. In vivo models in breast cancer research: progress, challenges and future directions. Dis Model Mech 2017;10:359-71.
115. Matthews SB, Sartorius CA. Steroid hormone receptor positive breast cancer patient-derived xenografts. Horm Cancer 2017;8:4-15.
116. du MS, Orsetti B, Bras-Goncalves R, et al. Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. Mol Oncol 2014;8:431-43.
117. Eirew P, Steif A, Khattra J, et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 2015;518:422-6.
118. Skibinski A, Kuperwasser C. The origin of breast tumor heterogeneity. Oncogene 2015;34:5309-16.
119. Dobrolecki LE, Airhart SD, Alferez DG, et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev 2016;35:547-73.
120. Finlay-Schultz J, Jacobsen BM, Riley D, et al. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res 2020;22:68.
121. Drobysheva D, Smith BA, McDowell M, Guillen KP, Ekiz HA, Welm BE. Transformation of enriched mammary cell populations with polyomavirus middle T antigen influences tumor subtype and metastatic potential. Breast Cancer Res 2015;17:132.
122. Maglione JE, Moghanaki D, Young LJ, et al. Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001;61:8298-305.
123. Diaz-Cruz ES, Sugimoto Y, Gallicano GI, Brueggemeier RW, Furth PA. Comparison of increased aromatase versus ERalpha in the generation of mammary hyperplasia and cancer. Cancer Res 2011;71:5477-87.
124. Bonner MR, Han D, Nie J, et al. Breast cancer risk and exposure in early life to polycyclic aromatic hydrocarbons using total suspended particulates as a proxy measure. Cancer Epidemiol Biomarkers Prev 2005;14:53-60.
125. Steck SE, Gaudet MM, Eng SM, et al. Cooked meat and risk of breast cancer--lifetime versus recent dietary intake. Epidemiology 2007;18:373-82.
126. Nie J, Beyea J, Bonner MR, et al. Exposure to traffic emissions throughout life and risk of breast cancer: the Western New York Exposures and Breast Cancer (WEB) study. Cancer Causes Control 2007;18:947-55.
127. Mordukhovich I, Beyea J, Herring AH, et al. Polymorphisms in DNA repair genes, traffic-related polycyclic aromatic hydrocarbon exposure and breast cancer incidence. Int J Cancer 2016;139:310-21.
128. Huggins C, Grand LC, Brillantes FP. Mammary cancer induced by a single feeding of polynuclear hyrocarbons, and its suppression. Nature 1961;189:204.
130. Zhang X, de Oliveira AF, Zhang H, et al. Maternal obesity increases offspring's mammary cancer recurrence and impairs tumor immune response. Endocr Relat Cancer 2020;27:469-82.
131. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990;62:244-78.
132. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007;8:R76.
133. Samuelson E, Nilsson J, Walentinsson A, Szpirer C, Behboudi A. Absence of Ras mutations in rat DMBA-induced mammary tumors. Mol Carcinog 2009;48:150-5.
134. Abba MC, Zhong Y, Lee J, et al. DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations. Oncotarget 2016;7:64289-99.
135. Hilakivi-Clarke LA, Wärri A, Bouker KB, et al. Effects of in utero exposure to ethinyl estradiol on tamoxifen resistance and breast cancer recurerence in a preclinical model. J Natl Cancer Inst 2017;109:1-11.
136. Cook KL, Soto-Pantoja DR, Clarke PAG, et al. Endoplasmic reticulum stress protein GRP78 modulates lipid metabolism to control drug sensitivity and antitumor immunity in breast cancer. Cancer Res 2016;76:5657-70.
137. de Assis S, Warri A, Cruz MI, et al. High-fat or ethinyl-oestradiol intake during pregnancy increases mammary cancer risk in several generations of offspring. Nat Commun 2012;3:1053.
138. Zhang X, Cook KL, Warri A, et al. Lifetime genistein intake increases the response of mammary tumors to Tamoxifen in rats. Clin Cancer Res 2017;23:814-24.
139. Yin Y, Bai R, Russell RG, et al. Characterization of medroxyprogesterone and DMBA-induced multilineage mammary tumors by gene expression profiling. Mol Carcinog 2005;44:42-50.
140. Mohibi S, Mirza S, Band H, Band V. Mouse models of estrogen receptor-positive breast cancer. J Carcinog 2011;10:35.
141. de Oliveira KD, Avanzo GU, Tedari MV, et al. Chemical carcinogenesis by DMBA (7,12-dimethylbenzanthracene) in female BALB/c mice: new facts. Brazil J Vet Res Animal Sci 2015;52:125-33.
142. Buqué A, Bloy N, Perez-Lanzón M, et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat Commun 2020;11:3819.
143. Le NA, Rossary A, Vasson MP. EO771, is it a well-characterized cell line for mouse mammary cancer model? Cancer Med 2020;9:8074-85.
144. Le NA, Koffi Y, Diab M, et al. EO771, the first luminal B mammary cancer cell line from C57BL/6 mice. Cancer Cell Int 2020;20:328.
145. Johnstone CN, Smith YE, Cao Y, et al. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Model Mech 2015;8:237-51.
146. Dekkers JF, van Vliet EJ, Sachs N, et al. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nat Protoc 2021;16:1936-65.
147. Houthuijzen JM, Jonkers J. Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment. Cancer Metastasis Rev 2018;37:577-97.
